# Producing Recombinant mRNA in Escherichia coli

> **NIH NIH R43** · E&E BIOCLUB LLC · 2024 · $300,518

## Abstract

PROJECT SUMMARY
The success of mRNA-based vaccines and their modular technology have propelled RNA-
based medicines from a relatively niche technology into the mainstream. As RNA-based
medicines research intensifies, the manufacturing capacity of RNA is strained. This issue is
exacerbated by the unprecedented advancement of RNA-based therapeutics into clinical
phases. The increased demand for mRNA-based medicines requires a scalable and cost-
effective manufacturing process with good yield and consistent quality. Currently, mRNA
manufacturing is dominated by enzymatic in vitro transcription (IVT). Although the IVT process
has various advantages, its cost and scalability are constrained by the need for multiple
expensive enzymes and chemical reagents.
Moreover, the lack of a standard process poses another challenge for IVT. A standardized
process for IVT is crucial as changes in concentrations of ribonucleoside triphosphate and
magnesium ions can dramatically affect RNA polymerase specificity, fidelity, and productivity.
Manufacturing RNA in vivo has proven more cost-effective and scalable than other methods.
However, intracellular RNA production has only been successful for double-strand circular
RNA or short molecules that can fit into specific stable RNA scaffolds, falling short for long
single-strand mRNA. Quick RNA degradation by intracellular RNases and the heterogeneity
of RNA transcripts within host cells hinder mRNA production in vivo and consequent
purification processes, respectively. Combinatorial approaches, including host cell
engineering, target RNA design, and a compatible downstream purification process, are
proposed to overcome these challenges. This application aims to develop an all-in-one
platform for intracellular overproduction of long, single-strand mRNA.

## Key facts

- **NIH application ID:** 11008720
- **Project number:** 1R43GM156257-01
- **Recipient organization:** E&E BIOCLUB LLC
- **Principal Investigator:** Hao Yu
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $300,518
- **Award type:** 1
- **Project period:** 2024-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11008720

## Citation

> US National Institutes of Health, RePORTER application 11008720, Producing Recombinant mRNA in Escherichia coli (1R43GM156257-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11008720. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*